---
title: "CASI Pharmaceuticals Closes Final US$5 Million Tranche of US$20 Million Convertible Notes"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283362109.md"
description: "CASI Pharmaceuticals has closed the final US$5 million tranche of its US$20 million convertible note financing with ETP Global III Fund LP. The 36-month note has a 12% annual interest rate and can be converted into shares at a price capped at US$2. Analysts rate CASIF stock as a Buy with a $4.00 price target, but Spark's AI Analyst gives it a Neutral score due to poor financial performance and high leverage. CASI focuses on developing CID-103 for organ transplant rejection and autoimmune diseases."
datetime: "2026-04-20T13:24:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283362109.md)
  - [en](https://longbridge.com/en/news/283362109.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283362109.md)
generator: "portal-rs"
---

# CASI Pharmaceuticals Closes Final US$5 Million Tranche of US$20 Million Convertible Notes

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

CASI Pharmaceuticals ( (CASIF) ) has issued an announcement.

CASI Pharmaceuticals said on April 20, 2026 that it has closed the fourth and final US$5 million tranche of its previously announced US$20 million convertible note financing with ETP Global III Fund LP, an entity controlled by chairman Wei-Wu He. The 36‑month note carries a 12% annual interest rate and can be converted into CASI ordinary shares at a volume-weighted average price capped at US$2 and floored at US$1, bolstering the company’s funding flexibility while introducing potential future equity dilution for shareholders.

The most recent analyst rating on (CASIF) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASIF Stock Forecast page.

**Spark’s Take on CASIF Stock**

According to Spark, TipRanks’ AI Analyst, CASIF is a Neutral.

The score is primarily weighed down by poor financial performance (declining revenue, ongoing losses, negative and worsening free cash flow, and very high leverage). Technicals are somewhat improved in the short term but remain weak versus longer-term trend levels, while valuation is difficult to support due to negative earnings and no dividend yield data.

To see Spark’s full report on CASIF stock, click here. 

**More about CASI Pharmaceuticals**

CASI Pharmaceuticals, Inc. is a Beijing-headquartered, clinical-stage biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody. The company is targeting indications in organ transplant rejection and autoimmune diseases, positioning itself in specialized immunology and transplant-related markets.

**Average Trading Volume:** 209,386

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $2.32M

See more insights into CASIF stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [CASIF.US](https://longbridge.com/en/quote/CASIF.US.md)

## Related News & Research

- [Safe: Shielded transactions with Bermuda enter beta early access - 03 Oct 2026](https://longbridge.com/en/news/300861381.md)
- [Greg Abel-Led Berkshire Hathaway Owns 3 Consumer Stocks. Here's the One I'd Buy First.](https://longbridge.com/en/news/300873098.md)
- [Western Digital vs. Sandisk: The Better Way to Play the Hard-Drive Side of the AI Storage Boom](https://longbridge.com/en/news/300870855.md)
- [Prediction: Enterprise Products Partners Will Hit 30 Years of Distribution Growth by Year-End 2028.](https://longbridge.com/en/news/300860608.md)
- [Constellation Brands Stock Forecast: Beer Demand Faces a Key Q2 Earnings Test](https://longbridge.com/en/news/300859275.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**